All News
#Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published papers re:IFN-I pathway activation assays, hence unable to perform meta-analyses of results.They proposed Consensus Terminology for IFN #research #EULAR2021 #POS0370 @RheumNow https://t.co/lbqy2xbEyt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2004 Grade A or B was predictive of damage in the median FU of 73 months. MMF use appeared to be protective #EULAR2021 #POS0705 @RheumNow https://t.co/VROqTTrzwY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on Placebo enrolled in Extension Study. Dr Saxena reported patients on VOC continued meaningful ⬇️in uPCR and stable eGFR up to 2yrs vs Placebo #EULAR2021 #POS0681 @RheumNow https://t.co/M5MX7tW2CA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces remaining)
🕒12:30 CEST / 11:30 UK
🧬 "Lupus, the next 10 years" 🔬where we will be joined by @edvital
📍Click EULAR Networking then Interest Group Discussion to join @EMEUNET https://t.co/6r7RYOi8VG
Chris Wincup chriswincup ( View Tweet)
Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #EULAR2021 #OP0228 #OP0230 @RheumNow 🤔
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of our patients with lupus. Future of #SLE research are in good hands 👌#NEXTGEN @edvital @GeorgeARobinson @pekor002 @dalilatm Matteo Boemi, Teona @eular_org https://t.co/eK4oiwlJZO
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU before 🔼lymphoma. 58/618 developed lymphoma. Predictors identified were⬆️Focus Score, cryoglobulin & parotid swelling. FS=>4 predicted earlier lymphoma #EULAR2021 #OP0291 @RheumNow https://t.co/yFFZpBRvji
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In case you're not convinced:
Another study showed HCQ protects SLE pts from death. Risk reduction in those taking antimalarials 83% vs. those who cannot take the drug (for any reason) 42%, yet 60% of patients are non-adherent
-study reviewed by Prof Dorner #EULAR2021 @rheumnow https://t.co/zBgCLipHPP
k dao KDAO2011 ( View Tweet)
Can we identify 1st Trimester predictors of adverse pregnancy outcome (APO) in #lupus? Dr Larosa studied women in 🇫🇷 (N=238; 98% on #HCQ; 86% had SLEDAI=0). 34(14%) had APO. Higher SLICC damage and LAC+ve predicted APO but not LLDAS/DORIS Remission #EULAR2021 #OP0295 @RheumNow https://t.co/423sSEKLFY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Why do black women with #lupus have poor #HRQoL? Dr Kimble used untargeted metabolomic profiling in N=23 black women SLE and N=21 black women nonSLE. The former had profiles consistent with⬇️energy production resulted in ⬆️fatigue and other symptoms #EULAR2021 #POS0173 @RheumNow https://t.co/GYzmpf8GwW
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
More novel target (IL23-i; Risankizumab) for #psoriaticarthritis👏. Dr Ostor presented results from Phase III KEEPsAKE2. 46% of patients were Bio-IR. 51.3% of RZB-treated vs 26.5% Placebo-tx achieved ACR20 response at 6mo (p<0.001). No major safety #EULAR2021 #OP0228 @RheumNow https://t.co/6AIGCNMApv
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Is Dissociation a component of #lupus brain fog ☁️? Dr Monahan administered DES scale (score =>25 = Dissociation) to N=339 pts; of which 97 (27%) had NPSLE. Only 13% had abnormal score. No difference in score btw NPSLE vs non-NPSLE #EULAR2021 #POS0709 @RheumNow https://t.co/aarL8gdCDM
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Israeli study of all cause mortality in PsA vs general population
⭐️no increased mortality in PsA group
⭐️leading causes of death was cancer in both groups
⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs
Abs#OP0219
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Bilgin presents on PLEX in AAV. I'm not a believer post-PEXIVAS despite attempts to slice and dice that data and this seems to show no evidence to change my mind @RheumNow #EULAR2021 Abstr#POS0255 https://t.co/U3zwt619lc
Richard Conway RichardPAConway ( View Tweet)
#POS0221 retrospective propensity score corrected observational study TOFA (n:156) vs. BARI (n:138): week 24: CDAI REM (see pic) BARI>TOFA. Factors of treatment resistence in TOFA: OR: Nr of prior bDMARD 1.77 & HAQ-DI 18.6
No such factors in BARI identified.
#EULAR2021 @RheumNow https://t.co/u9Nati2ZJO
Paul Studenic Stiddyo ( View Tweet)
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Dr. John Cush RheumNow ( View Tweet)
➡️Percentage achieving PASI75 (not H2H comparison):
⭐️GUS > IXE > INF > SEC > UST > GOL 100mg >ADA> CTZ > TOFA> GOL 50 mg > ETN > APR
⭐️Amongst TNFi (not H2H): INF > GOL > ADA > CTZ > ETN
Great talk by Dr. L Coates on personalized tx approach for PsA.
#EULAR2021 @RheumNow https://t.co/jMGaBlg3Iy
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️%age achieving ACR20 (not H2H comparisons):
⭐️GUS > IXE > TOFA > CTZ > ETN > INF > ADA > SEC > GOL > UST > APR
➡️ Choosing therapies in AxSpA:
⭐️TNFi (ADA), IL17i (SEC), Jaki (UPA); however, axPsA may be different than AxSpA. Need more trials to assess!
#EULAR2021 @RheumNow https://t.co/toMyS3uPAZ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
How to choose therapy for psoriatic dz?
➡️Should be a personalized approach based on co-morbidities
➡️Below drugs are approved for primary therapy of co-morbid condition:
⭐️IBD: SSZ, ADA, INF. GOL for UC, UST for Crohn's
⭐️Uveitis: GCs & INF preferred, ADA
#EULAR2021 @RheumNow https://t.co/inN07QP9t4
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Step-wise vs rapid escalator approach for PsO & PsA?
⭐️CONTROL study:
➡️bDMARD-naive active PsA w/ IR to MTX for at least 4w randomized to ADA+MTX vs escalated MTX (avg dose 21.8 mg/wk, 55% PO, 36% SQ)
➡️41.5% MDA at wk 16 w/ ADA+MTX vs 13.1%
#EULAR2021 @RheumNow https://t.co/uw5BFQGqNV
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)